ArticleNature2020
SARS-CoV-2-reactive T cells in healthy donors and patients with COVID-19.
Open access · bronzeAbstract read
In one paragraph
Article in Nature, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 884 papers, 2 of them syntheses that pooled it.
0numbers the graph read from it
0cells of the map it votes in
884citing papers in PubMed, 2 pooled it
31.7field-weighted citation impact, top 1% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
884 citing papers in PubMed, 2 syntheses or guidelines pooled it, 1,390 citations in OpenAlex.
- Diagnostic Efficacy of 11 SARS-CoV-2 Serological Assays for COVID-19: A Meta-Analysis and Adjusted Indirect Comparison of Diagnostic Test Accuracy.Immunity, inflammation and disease · 2024Pooled it
- Prepandemic cross-reactive humoral immunity to SARS-CoV-2 in Africa: Systematic review and meta-analysis.International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases · 2023Pooled it
- Phase I/II trial of a peptide-based COVID-19 T-cell activator in patients with B-cell deficiency.Nature communications · 2023Trial
- Human memory T cell dynamics after aluminum-adjuvanted inactivated whole-virion SARS-CoV-2 vaccination.Scientific reports · 2023Trial
- Broad cross-T cell immunity between emerging SARS-CoV-2 serotypes waved by spike-signature mutations.Emerging microbes & infections · 2026Article
- Review
- Integrated Assessment of Humoral and Cellular SARS-CoV-2 Immunity Using ELISA and a Gold Nanoparticle-Based IGRA.International journal of molecular sciences · 2026Article
- Article
- No clear evidence of PFAS-induced immunomodulation in SARS-CoV-2-specific human T cell responses following vaccination.Archives of toxicology · 2026Article
- Reproducible detection of antigen-specific T cells and Tregs via standardized and automated activation-induced marker assay workflows.Cell reports methods · 2026Article
- Computational identification of antigen-specific T cell groups through generative epitope modeling.iScience · 2026Article
- Article
- Serial vaccination expands and refines human CD4bioRxiv : the preprint server for biology · 2026Article
- DNA origami vaccine nanoparticles improve humoral and cellular immune responses to infectious diseases.Nature biomedical engineering · 2026Article
- A Lung-Immune Dual-Humanized Mouse Using Cryopreserved Tissue Enables Infection and Immune Profiling of Human Common Cold Coronaviruses.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- Inference of SARS-CoV-2 exposure biomarkers using large-scale T-cell repertoire profiling.Genome medicine · 2026Article
- Pre-COVID-19 ex vivo cross-reactive IFN-γ cellular response to SARS-CoV-2 spike overlapping peptides is more prevalent among Kenyan compared to Swedish adults.BMC infectious diseases · 2026Article
- Effect of PEI25k/DOTAP/cholesterol liposomal formulation on the immunogenicity of SARS-CoV-2 spike protein-encoding DNA vaccine.Biotechnologia · 2026Article
- Article
- Long-persisting SARS-CoV-2 spike-specific CD4Nature communications · 2025Article
824 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
33 authors at 9 institutions in 2 countries.
Julian Braun *Si-M/'Der Simulierte Mensch', Technische Universität Berlin and Charité-Universitätsmedizin Berlin, Berlin, Germany.
Lucie Loyal *Si-M/'Der Simulierte Mensch', Technische Universität Berlin and Charité-Universitätsmedizin Berlin, Berlin, Germany.
Marco Frentsch *Department of Hematology, Oncology and Tumor Immunology, Charité-Universitätsmedizin Berlin, Berlin, Germany.
Daniel WendischBerlin Institute of Health (BIH), Berlin, Germany.ORCID http://orcid.org/0000-0003-1968-5751
Philipp GeorgDepartment of Infectious Diseases and Respiratory Medicine, Charité-Universitätsmedizin Berlin, Berlin, Germany.
Florian KurthBerlin Institute of Health (BIH), Berlin, Germany.ORCID http://orcid.org/0000-0002-3807-473X
Stefan HippenstielBerlin Institute of Health (BIH), Berlin, Germany.ORCID http://orcid.org/0000-0002-5146-1064
Manuela DingeldeySi-M/'Der Simulierte Mensch', Technische Universität Berlin and Charité-Universitätsmedizin Berlin, Berlin, Germany.
Beate KruseSi-M/'Der Simulierte Mensch', Technische Universität Berlin and Charité-Universitätsmedizin Berlin, Berlin, Germany.
Florent FauchereSi-M/'Der Simulierte Mensch', Technische Universität Berlin and Charité-Universitätsmedizin Berlin, Berlin, Germany.ORCID http://orcid.org/0000-0002-1955-6362
Emre BaysalSi-M/'Der Simulierte Mensch', Technische Universität Berlin and Charité-Universitätsmedizin Berlin, Berlin, Germany.
Maike MangoldSi-M/'Der Simulierte Mensch', Technische Universität Berlin and Charité-Universitätsmedizin Berlin, Berlin, Germany.
Larissa HenzeSi-M/'Der Simulierte Mensch', Technische Universität Berlin and Charité-Universitätsmedizin Berlin, Berlin, Germany.
Roland LausterSi-M/'Der Simulierte Mensch', Technische Universität Berlin and Charité-Universitätsmedizin Berlin, Berlin, Germany.
Marcus A MallMedical Biotechnology, Institute for Biotechnology, Technische Universität Berlin, Berlin, Germany.
Kirsten BeyerMedical Biotechnology, Institute for Biotechnology, Technische Universität Berlin, Berlin, Germany.
Jobst RöhmelMedical Biotechnology, Institute for Biotechnology, Technische Universität Berlin, Berlin, Germany.
Sebastian VoigtDepartment of Infectious Diseases, Robert Koch Institut, Berlin, Germany.ORCID http://orcid.org/0000-0003-1544-9903
Jürgen SchmitzMiltenyi Biotec, Bergisch Gladbach, Germany.
Stefan MiltenyiMiltenyi Biotec, Bergisch Gladbach, Germany.
Ilja DemuthInterdisciplinary Metabolism Center, Biology of Aging (BoA) group, Charité-Universitätsmedizin Berlin, Berlin, Germany.
Marcel A MüllerInstitute of Virology, Charité-Universitätsmedizin Berlin, Berlin, Germany.ORCID http://orcid.org/0000-0003-2242-5117
Andreas HockeBerlin Institute of Health (BIH), Berlin, Germany.
Martin WitzenrathBerlin Institute of Health (BIH), Berlin, Germany.
Norbert SuttorpBerlin Institute of Health (BIH), Berlin, Germany.
Florian KernDepartment of Clinical and Experimental Medicine, Brighton and Sussex Medical School, Brighton, UK.ORCID http://orcid.org/0000-0002-0368-8408
Ulf ReimerJPT Peptide Technologies, Berlin, Germany.
Holger WenschuhJPT Peptide Technologies, Berlin, Germany.
Christian DrostenDepartment of Pediatric Pulmonology, Immunology and Critical Care Medicine, Charité-Universitätsmedizin Berlin, Berlin, Germany.ORCID http://orcid.org/0000-0001-7923-0519
Victor M CormanInstitute of Virology, Charité-Universitätsmedizin Berlin, Berlin, Germany.ORCID http://orcid.org/0000-0002-3605-0136
Claudia Giesecke-ThielMax Planck Institute for Molecular Genetics, Berlin, Germany. giesecke@molgen.mpg.de.ORCID http://orcid.org/0000-0002-5927-7018
Leif Erik SanderBerlin Institute of Health (BIH), Berlin, Germany. leif-erik.sander@charite.de.ORCID http://orcid.org/0000-0002-0476-9947
Andreas ThielSi-M/'Der Simulierte Mensch', Technische Universität Berlin and Charité-Universitätsmedizin Berlin, Berlin, Germany. andreas.thiel@charite.de.ORCID http://orcid.org/0000-0002-5515-4002
Berlin-Brandenburger Centrum für Regenerative Therapien · DEBerlin Institute of Health at Charité - Universitätsmedizin Berlin · DECharité - Universitätsmedizin Berlin · DETechnische Universität Berlin · DEMiltenyi Biotec (Germany) · DEUniversität Hamburg · DEBrighton and Sussex Medical School · GBMax Planck Institute for Molecular Genetics · DERobert Koch Institute · DE
Funding
No grant is acknowledged in the PubMed record.
Abstract
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has caused the rapidly unfolding coronavirus disease 2019 (COVID-19) pandemic
Indexed as
AdultAgedAged, 80 and overBetacoronavirusCD4-Positive T-LymphocytesCell LineCoronavirus 229E, HumanCoronavirus InfectionsCoronavirus NL63, HumanCoronavirus OC43, HumanCOVID-19Cross ReactionsEpitopes, T-LymphocyteFemaleHealthy VolunteersHumansEpitopes, T-LymphocyteSpike Glycoprotein, Coronavirusspike protein, SARS-CoV-2
Identifiers
What OpenQuestion holds
Textmetadata
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.